Clinical trials: Double Incontinence
Overactive Bladder
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
- Trial name
- NCT00350636
- Testing
- Oxybutynin topical gel
- Where
- 63 sites in United States
- Volunteers
- 789 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder, Urinary Incontinence
Low-level Light Therapy for Overactive Bladder and Urinary Incontinence
This study aims to evaluate the effectiveness of a self-therapeutic approach of skin adhesive low-level light therapy (LLLT) in females with Overactive Bladder (OAB) and Urinary Incontinence (UI)
- Trial name
- NCT02980328
- Testing
- Low-level light therapy
- Where
- 2 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Hospital
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Urinary Tract Infections
Nitrofurantoin and Urinary Tract Infections (UTIs)
Urinary tract infection (UTI) is the most common complication after surgery for prolapse or urinary incontinence. UTIs are painful and have the potential to turn into kidney infections.
- Trial name
- APPIC (NCT00678041)
- Testing
- Nitrofurantoin
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Urinary Incontinence
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
- Trial name
- NCT00139724
- Testing
- tolterodine extended release capsule
- Where
- 7 sites in China
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
The current study will investigate the comparative efficacy, safety and patient satisfaction of intradetrusor injections BOTOX® injections (200U) versus placebo (saline) injections in the treatment of OAB secondary to benign…
- Trial name
- BTX0621 (NCT00479596)
- Testing
- Botox
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Urological Sciences Research Foundation
Stress Urinary Incontinence, Surgical Incision
Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery
This study will compare the use of a dual-agent local analgesic (bupivacaine-meloxicam) for abdominal incisions in patients undergoing retropubic mid-urethral sling surgery to see if narcotic usage and pain are impacted.
- Conditions
- Stress Urinary Incontinence, Surgical Incision, Pain Vulva
- Trial name
- NCT05702827
- Testing
- Bupivacaine-Meloxicam
- Where
- 2 sites in United States
- Volunteers
- 148 people
- Sponsor
- TriHealth Inc.
Stress Urinary Incontinence
Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence
GTx-024 is an orally bioavailable and tissue-selective nonsteroidal selective androgen receptor modulator (SARM) that has demonstrated androgenic and anabolic activity and is currently being evaluated as a potential treatment for…
- Trial name
- ASTRID (NCT03241342)
- Testing
- GTx 024
- Where
- 62 sites in United States
- Volunteers
- 491 people
- Sponsor
- GTx
Overactive Bladder
SSR240600C Treatment in Women With Overactive Bladder
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
- Trial name
- BILADY (NCT00564226)
- Testing
- SSR240600C, tolterodine
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 345 people
- Sponsor
- Sanofi
Urinary Incontinence, Overactive Bladder
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult…
- Trial name
- CONTENT1 (NCT02660138)
- Testing
- Botulinum toxin type A
- Where
- 81 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Ipsen
Urinary Incontinence, Urinary Bladder, Overactive
516-BOTOX Urinary Incontinence Detrusor
The specific aim of this study is to evaluate the safety and efficacy of each of 2 dosages of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic…
- Trial name
- NCT00850733
- Sponsor
- Veterans Medical Research Foundation
Stress Urinary Incontinence
Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence
Stress Urinary Incontinence (SUI) is described as an uncontrolled loss of urine which happens when physical activities such as running, jumping and lifting etc are carried out or when increased pressure to the bladder in everyday…
- Trial name
- NCT02214784
- Testing
- Active Neurotech Vital, Modified Neurotech Vital Device
- Where
- 3 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Atlantic Therapeutics
Fecal Incontinence, Spinal Cord Injury
The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients
This is an double blinded, cross-over study to determine the effect of Oxymetazoline gel on anal resting pressure and fecal incontinence in patients with spinal cord injury.
- Trial name
- NCT02299557
- Testing
- Oxymetazoline gel
- Where
- Hungary
- Volunteers
- 19 people
- Sponsor
- RDD Pharma Ltd
Urinary Incontinence
Effect of Pollen Extract on Urinary Incontinence
Study with food supplement to assess the eficacy of pollen extract on Urinary Incontinence
- Trial name
- NCT03438422
- Testing
- Pollen extract
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Dr. Santiago Palacios
Urinary Incontinence, Stress
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
This is a clinical trial to study the safety and effectiveness of Autologous Muscle Derived Cells for Urinary Sphincter Repair (AMDC-USR) for the treatment of female stress urinary incontinence (SUI).
- Trial name
- NCT01382602
- Testing
- AMDC-USR
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 150 people
- Sponsor
- Cook MyoSite
Fecal Incontinence
Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects
A total of 26 healthy elderly male and female subjects will receive both 10 mg NRL001 in a 2 g rectal suppository and placebo in this double-blind, cross-over study.
- Trial name
- NCT01099683
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Norgine
Overactive Bladder (OAB)
RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder
This Phase 2b study is a prospective, multicenter, double blind, randomized, placebo and sham controlled trial to assess the safety, efficacy and dose response of NT 201 delivered by the Vibe System in participants with…
- Trial name
- RELIEVE (NCT07553065)
- Testing
- NT 201 200U and Vibe System, NT 201 300U and Vibe System
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Vensica Therapeutics Ltd.
Chronic Constipation
To Determine the Effect of Forlax® Treatment in Children With Chronic Constipation Who May Also Suffer From Soiling/ Faecal Incontinence.
The purpose of this study is to determine whether Forlax® is more effective than placebo in relieving chronic constipation in children who may also suffer from soiling or faecal incontinence.
- Trial name
- NCT00255372
- Testing
- PEG 4000 (Forlax®)
- Where
- 2 sites in Thailand
- Volunteers
- 88 people
- Sponsor
- Ipsen
Depression
The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients
Through this study, the investigators are to demonstrate the superiority of Escitalopram over placebo for the prevention of poststroke depression in patients with acute stroke The primary hypothesis of this study is; This study…
- Trial name
- EMOTION (NCT01278498)
- Testing
- Escitalopram, sugar pill
- Where
- 16 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Asan Medical Center
Urinary Incontinence, Overactive Bladder
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)
This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.
- Trial name
- NCT00290563
- Testing
- MK0594
- Volunteers
- 557 people
- Sponsor
- Vyne Therapeutics Inc.